Keybanc maintains Xcel Energy (NASDAQ:XEL) with a Overweight and raises the price target from $74 to $75.
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting With FDA; Announces ‘Alignment with the FDA on a regulatory path forward for the continued development of tebipenem Hbr’
Alignment with the FDA on a regulatory path forward for the continued development of tebipenem Hbr
FDA feedback indicates positive results from a single additional Phase 3 clinical trial in patients with
